These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 34975317)

  • 1. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 2. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
    Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W
    Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
    Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
    Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of
    Li JH; Wu X; Ni X; Li YX; Xu L; Hao XY; Zhao W; Zhu XX; Yin XY
    Clin Transl Med; 2023 Mar; 13(3):e1213. PubMed ID: 36855786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling.
    Lobe C; Vallette M; Arbelaiz A; Gonzalez-Sanchez E; Izquierdo L; Pellat A; Guedj N; Louis C; Paradis V; Banales JM; Coulouarn C; Housset C; Vaquero J; Fouassier L
    Hepatology; 2021 Dec; 74(6):3194-3212. PubMed ID: 34297412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma.
    Kunou S; Shimada K; Takai M; Sakamoto A; Aoki T; Hikita T; Kagaya Y; Iwamoto E; Sanada M; Shimada S; Hayakawa F; Oneyama C; Kiyoi H
    Oncogene; 2021 Jun; 40(23):3989-4003. PubMed ID: 33994542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
    Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
    BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.
    Yuan X; Li J; Coulouarn C; Lin T; Sulpice L; Bergeat D; De La Torre C; Liebe R; Gretz N; Ebert MPA; Dooley S; Weng HL
    Br J Cancer; 2018 Nov; 119(11):1358-1366. PubMed ID: 30420613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
    Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SP1-induced HOXD-AS1 promotes malignant progression of cholangiocarcinoma by regulating miR-520c-3p/MYCN.
    Li J; Jiang X; Li Z; Huang L; Ji D; Yu L; Zhou Y; Cui Y
    Aging (Albany NY); 2020 Aug; 12(16):16304-16325. PubMed ID: 32857725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HS6ST1 overexpressed in cancer-associated fibroblast and inhibited cholangiocarcinoma progression.
    Hu S; Xia C; Zou H; Ren W; Liu L; Wang L; Kang Q; He K; Wang T; Zhang X
    Dig Liver Dis; 2023 Aug; 55(8):1114-1125. PubMed ID: 36586771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment.
    Zhou Y; Xu L; Wang Z; Liu H; Zhang X; Shu C; Zhang M; Wang T; Xu X; Pu X; He J; Wang P; Qiu Y; Xu G; Zou X; Zhu Y; Wang L
    Theranostics; 2022; 12(8):3911-3927. PubMed ID: 35664077
    [No Abstract]   [Full Text] [Related]  

  • 16. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
    Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
    Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells.
    Utaijaratrasmi P; Vaeteewoottacharn K; Tsunematsu T; Jamjantra P; Wongkham S; Pairojkul C; Khuntikeo N; Ishimaru N; Sirivatanauksorn Y; Pongpaibul A; Thuwajit P; Thuwajit C; Kudo Y
    Mol Cancer; 2018 Jan; 17(1):10. PubMed ID: 29347950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest.
    Mancarella S; Gigante I; Pizzuto E; Serino G; Terzi A; Dituri F; Maiorano E; Vincenti L; De Bellis M; Ardito F; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2024 Oct; 43(1):286. PubMed ID: 39415286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.